Acute myeloid leukemia remains one of the most difficult blood cancers to treat, particularly for older patients or those with other health conditions who cannot tolerate intensive chemotherapy. For these patients, treatment options are limited and outcomes poor. New interim data from Aptevo Therapeutics' ongoing RAINIER clinical trial suggest its investigational therapy mipletamig may address this unmet need by adding clinical benefit to standard frontline treatment while maintaining a favorable safety profile.
Across evaluable frontline AML patients treated to date, the combination of mipletamig with venetoclax and azacitidine delivered an 86% clinical benefit rate, including a 79% remission rate. In AML, remission typically means leukemia cells have been reduced to very low levels in the bone marrow, either as complete remission or complete remission with incomplete blood count recovery. Notably, 55% of patients who achieved remission reached MRD-negative status, meaning highly sensitive tests could not detect any remaining leukemia cells. Achieving MRD negativity is considered an important marker of deeper disease control and potential for longer-lasting responses.
Equally significant is the therapy's safety profile. No patients treated to date have experienced cytokine release syndrome, a common and potentially serious immune reaction that can force patients to discontinue therapy. Avoiding CRS is especially important for drugs intended for combination use, where safety and tolerability are key to keeping patients on treatment. The company said the emerging data suggest mipletamig may enhance the current frontline AML treatment approach, improving patient responses while maintaining needed safety, especially for older or medically unfit patients.
Mipletamig is a bispecific antibody designed to serve two purposes simultaneously. One side targets CD123, a marker commonly found on AML leukemia cells, while the other connects with T-cells, the immune system's natural cancer fighters. By bringing these together, the therapy helps direct the immune system to attack leukemia cells. Aptevo says this targeted approach activates the immune response against AML while maintaining a safety profile that allows combination with existing frontline treatments.
The RAINIER trial is evaluating mipletamig in combination with venetoclax and azacitidine in newly diagnosed AML patients who are older or unable to receive intensive chemotherapy. The study is being conducted in two stages, beginning with a phase 1b portion to determine optimal dose, followed by a larger phase 2 study to further evaluate effectiveness. AML affects approximately 22,000 people in the United States annually and remains one of the most aggressive adult leukemias. For patients who cannot tolerate intensive treatment, advances that improve outcomes without adding significant toxicity remain crucial.
This content was originally published on Benzinga. Read further disclosures here. View the original release on www.newmediawire.com.
